Lillys

Lilly’s new Alzheimer’s drug could generate $7.1B in sales: analyst (NYSE:LLY)

jetcityimage/iStock Editorial via Getty Images Eli Lilly’s (NYSE:LLY) newly approved Alzheimer’s drug Kisunla could generate peak sales of up to $7.1B for the company and will help diversify the drugmaker’s revenue stream, according to BMO. Kisunla, also known as donanemab, will be priced at $32,000 per year, with each vialContinue Reading

ResMed cut at Oppenheimer after Lilly’s sleep apnea data

In: Finance

Pgiam/iStock via Getty Images Oppenheimer downgraded respiratory device maker ResMed (NYSE:RMD) to Perform from Outperform on Tuesday, citing an “air pocket” for the stock in the wake of encouraging data for Eli Lilly’s (NYSE:LLY) weight loss therapy tirzepatide in obstructive sleep apnea (OSA). The maker of CPAP (continuous positive airwayContinue Reading

Lillys

Lilly’s new Alzheimer’s drug could generate $7.1B in sales: analyst (NYSE:LLY)

ResMed cut at Oppenheimer after Lilly’s sleep apnea data

Responsible AI in action: How Data Reply red teaming supports generative AI safety on AWS | Amazon Web Services

InterVision accelerates AI development using AWS LLM League and Amazon SageMaker AI | Amazon Web Services